An FDA advisory committee voted against Otsuka's bid for brexpiprazole to become the first new therapy for post-traumatic stress disorder in more than 20 years. (Shutterstock)
Learn what's happening at the US FDA. On the go.
Derrick Gingery and the team bring you a weekly "Drug Fix".
